Cemiplimab Injection [Libtayo]
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Feb 18, 2021 → Dec 30, 2024
NCT ID
NCT04679480About Cemiplimab Injection [Libtayo]
Cemiplimab Injection [Libtayo] is a phase 2 stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04679480. Target conditions include Basal Cell Carcinoma.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04679480 | Phase 2 | Active |
Competing Products
20 competing products in Basal Cell Carcinoma